Produktname:(R)-2-tert-Butyl 8a-methyl 6-oxo-3,4,6,7,8,8a-hexahydroisoquinoline-2,8a(1H)-dicarboxylate

IUPAC Name:2-tert-butyl 8a-methyl (8aR)-6-oxo-1,2,3,4,6,7,8,8a-octahydroisoquinoline-2,8a-dicarboxylate

CAS:445312-74-3
Molekulare Formel:C16H23NO5
Reinheit:97%
Katalognummer:CM229457
Molekulargewicht:309.36

Packungseinheit Verfügbarer Vorrat Preis($) Menge
CM229457-10g in stock ƿIJŗǙ

Nur für den Einsatz in Forschung und Entwicklung..

Anfrage-Formular

   refresh    

Produkt-Details

CAS-Nr.:445312-74-3
Molekulare Formel:C16H23NO5
Schmelzpunkt:-
SMILES-Code:O=C(N(CCC1=C2)C[C@@]1(C(OC)=O)CCC2=O)OC(C)(C)C
Dichte:
Katalognummer:CM229457
Molekulargewicht:309.36
Siedepunkt:
Mdl-Nr.:
Lagerung:

Column Infos

Relacorilant
Corcept completes enrollment in phase 3 Gradient trial of Relacorilant in patients with Adrenal Cushing’s Syndrome. Cushing's disease or hypercortisolism is a rare endocrine disorder that occurs when a pituitary adenoma makes excessive cortisol. Cortisol exerts its functions by binding to the glucocorticoid receptor (GR).
Relacorilant is a selective glucocorticoid receptor modulator (SGRM) in clinical development to prevent the effects of high cortisol. Relacorilant is being studied in various serious disorders, including ovarian, adrenal and prostate cancer and Cushing’s syndrome.